Skip to content Skip to footer

2020

Journal Article

Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer

Fong, Lawrence, Hotson, Andrew, Powderly, John D., Sznol, Mario, Heist, Rebecca S., Choueiri, Toni K., George, Saby, Hughes, Brett G. M., Hellmann, Matthew D., Shepard, Dale R., Rini, Brian I., Kummar, Shivaani, Weise, Amy M., Riese, Matthew J., Markman, Ben, Emens, Leisha A., Mahadevan, Daruka, Luke, Jason J., Laport, Ginna, Brody, Joshua D., Hernandez-Aya, Leonel, Bonomi, Philip, Goldman, Jonathan W., Berim, Lyudmyla, Renouf, Daniel J., Goodwin, Rachel A., Munneke, Brian, Ho, Po Y., Hsieh, Jessica ... Miller, Richard A. (2020). Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discovery, 10 (1), 40-53. doi: 10.1158/2159-8290.CD-19-0980

Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer

2019

Journal Article

Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib

Chan, Sarah, Ahern, Elizabeth, Chaudhry, Sarah and Hughes, Brett (2019). Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib. BMJ case reports, 12 (12) e232868, e232868. doi: 10.1136/bcr-2019-232868

Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib

2019

Journal Article

An update: circulating tumor cells in head and neck cancer

Kulasinghe, Arutha, Hughes, Brett G. M., Kenny, Liz and Punyadeera, Chamindie (2019). An update: circulating tumor cells in head and neck cancer. Expert Review of Molecular Diagnostics, 19 (12), 1109-1115. doi: 10.1080/14737159.2020.1688145

An update: circulating tumor cells in head and neck cancer

2019

Journal Article

EGFR mutations in lung cancer: not all equal in the eyes of the immune system?

Fong, Kwun M., Hughes, Brett G. M., Lwin, Zarnie and Yang, Ian A. (2019). EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 7 (S8) S326, S326-S326. doi: 10.21037/atm.2019.09.132

EGFR mutations in lung cancer: not all equal in the eyes of the immune system?

2019

Journal Article

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)

Ahern, Elizabeth, Cubitt, Annette, Ballard, Emma, Teng, Michele W. L., Dougall, William C., Smyth, Mark J., Godbolt, David, Naidoo, Rishendran, Goldrick, Amanda and Hughes, Brett G. M. (2019). Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Trials, 20 (1) 753, 753. doi: 10.1186/s13063-019-3951-x

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)

2019

Journal Article

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, Barbara, Harrington, Kevin J., Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G. M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Roy, Ananya, Zhang, Yayan, Gumuscu, Burak, Cheng, Jonathan D., Jin, Fan, Rischin, Danny, Lerzo, Guillermo, Tatangelo, Marcelo, Varela, Mirta, Zarba, Juan Jose, Boyer, Michael ... on behalf of the KEYNOTE-048 Investigators (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet, 394 (10212), 1915-1928. doi: 10.1016/S0140-6736(19)32591-7

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

2019

Journal Article

Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC

Moroney, Laura B., Ward, Elizabeth C., Helios, Jennifer, Crombie, Jane, Burns, Clare L., Blake, Claire, Comans, Tracy, Chua, Benjamin, Kenny, Lizbeth and Hughes, Brett G. M. (2019). Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC. Supportive Care in Cancer, 28 (4), 1867-1876. doi: 10.1007/s00520-019-04992-x

Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC

2019

Journal Article

Traveling with cancer: a guide for oncologists in the modern world

Heng, Sharon, Hughes, Brett, Hibbert, Michael, Khasraw, Mustafa and Lwin, Zarnie (2019). Traveling with cancer: a guide for oncologists in the modern world. Journal of Global Oncology, 5 (5) Y, 1-10. doi: 10.1200/JGO.19.00029

Traveling with cancer: a guide for oncologists in the modern world

2019

Journal Article

The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer

Turner, Jane, Yates, Patsy, Kenny, Lizbeth, Gordon, Louisa G., Burmeister, Bryan, Hughes, Brett G. M., McCarthy, Alexandra L., Perry, Chris, Chan, Raymond J., Paviour, Alana, Skerman, Helen, Batstone, Martin and Mackenzie, Lisa (2019). The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer. Supportive Care in Cancer, 27 (12), 4627-4637. doi: 10.1007/s00520-019-04748-7

The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer

2019

Journal Article

Patterns of care for stage III non–small cell lung cancer in Australia

Parente, Phillip, Chan, Bryan A., Hughes, Brett G. M., Jasas, Kevin, Joshi, Rohit, Kao, Steven, Hegi-Johnson, Fiona, Hui, Rina, McLaughlin-Barrett, Sara, Nordman, Ina and Stone, Emily (2019). Patterns of care for stage III non–small cell lung cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 15 (3), 93-100. doi: 10.1111/ajco.13140

Patterns of care for stage III non–small cell lung cancer in Australia

2018

Journal Article

Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma

Metaxas, Yannis, Rivalland, Gareth, Mauti, Laetitia A., Klingbiel, Dirk, Kao, Steven, Schmid, Sabine, Nowak, Anna K., Gautschi, Oliver, Bartnick, Tammo, Hughes, Brett G., Bouchaab, Hasna, Rothschild, Sacha I., Pavlakis, Nick, Wolleb, Sibylle, Petrausch, Ulf, O'Byrne, Kenneth, Froesch, Patrizia, Löffler-Baumann, Melanie, Pratsch-Peter, Susanne, Russell, Prudence, Mingrone, Walter, Savic, Spasenija, Thapa, Bibhusal, Früh, Martin, Pless, Miklos, von Moos, Roger and John, Thomas (2018). Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Oncology, 13 (11), 1784-1791. doi: 10.1016/j.jtho.2018.08.007

Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma

2018

Journal Article

Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study

Tran, Q., Schimdt, A., Lwin, Z. and Hughes, B. G. M. (2018). Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study. Annals of Oncology, 29, viii756. doi: 10.1093/annonc/mdy424.088

Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study

2018

Journal Article

PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., Rabinowits, G., Thai, A. A., Dunn, L. A., Hughes, B. G. M., Khushalani, N. I., Modi, B., Schadendorf, D., Gao, B., Seebach, F., Li, S., Li, J., Mathias, M., Booth, J., Mohan, K., Stankevich, E., Babiker, H. M., Brana, I., Gil-Martin, M., Homsi, J. ... Fury, M. G. (2018). PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. New England Journal of Medicine, 379 (4), 341-351. doi: 10.1056/NEJMoa1805131

PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

2018

Journal Article

Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns

Moroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Burns, Clare L., Yeo, Shu Qi, Pelecanos, Anita, Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth, Chua, Benjamin and Hughes, Brett G. M. (2018). Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. Supportive Care in Cancer, 27 (2), 1-9. doi: 10.1007/s00520-018-4352-5

Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns

2018

Journal Article

CXCR4 and PD-1 expression in head and neck cancer with perineural spread

Barnett, Catherine M., Sommerville, Ryan S., Lin, Charles, Ratnayake, Gishan, Hughes, Brett and Taheri, Touraj (2018). CXCR4 and PD-1 expression in head and neck cancer with perineural spread. Journal of Neurological Surgery, Part B: Skull Base, 80 (01), 018-022. doi: 10.1055/s-0038-1660846

CXCR4 and PD-1 expression in head and neck cancer with perineural spread

2018

Journal Article

Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns

Moroney, Laura B., Helios, Jennifer, Ward, Elizabeth C., Crombie, Jane, Pelecanos, Anita, Burns, Clare L., Spurgin, Ann-Louise, Blake, Claire, Kenny, Lizbeth, Chua, Benjamin and Hughes, Brett G. M. (2018). Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns. Head & Neck, 40 (9), 1955-1966. doi: 10.1002/hed.25182

Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns

2018

Journal Article

Osimertinib in Untreated <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer

Soria, J. -C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. -C., Gray, J. E., Lee, S. -M., Hodge, R., Marotti, M., Rukazenkov, Y., Ramalingam, S. S., Boyer, Michael, Lee, Chee, Hughes, Brett, O'Byrne, Kenneth, Briggs, Peter ... Nguyen, Nhung (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378 (2), 113-125. doi: 10.1056/NEJMoa1713137

Osimertinib in Untreated <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer

2017

Journal Article

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

McKeage, Mark J., Kotasek, Dusan, Markman, Ben, Hidalgo, Manuel, Millward, Michael J., Jameson, Michael B., Harris, Dean L., Stagg, Robert J., Kapoun, Ann M., Xu, Lu and Hughes, Brett G. M. (2017). Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Targeted Oncology, 13 (1), 1-10. doi: 10.1007/s11523-017-0543-0

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

2017

Journal Article

Clinical guidance for Radioiodine Refractory Differentiated Thyroid Cancer

Gild, Matti L., Topliss, Duncan J., Learoyd, Diana, Parnis, Francis, Tie, Jeanne, Hughes, Brett, Walsh, John P., McLeod, Donald Sa, Clifton-Bligh, Roderick J. and Robinson, Bruce G. (2017). Clinical guidance for Radioiodine Refractory Differentiated Thyroid Cancer. Clinical Endocrinology, 88 (4), 529-537. doi: 10.1111/cen.13508

Clinical guidance for Radioiodine Refractory Differentiated Thyroid Cancer

2017

Journal Article

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria

Gandhi, Leena, Ou, Sai-Hong Ignatius, Shaw, Alice T., Barlesi, Fabrice, Dingemans, Anne-Marie C., Kim, Dong-Wan, Camidge, D. Ross, Hughes, Brett G. M., Yang, James C. -H., de Castro, Javier, Crino, Lucio, Lena, Herve, Do, Pascal, Golding, Sophie, Bordogna, Walter, Zeaiter, Ali, Kotb, Ahmed and Gadgeel, Shirish (2017). Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria. European Journal of Cancer, 82, 27-33. doi: 10.1016/j.ejca.2017.05.019

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria